project id: TCGA-READ; case submitter id: TCGA-AF-A56N; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; normal tumor genotype snp match: Yes; age at index: 47; days to birth: -17480; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1965; age at diagnosis: 17480; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage IIA; ajcc pathologic t: T3; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 360.0; icd 10 code: C19; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Rectosigmoid junction; synchronous malignancy: No; tissue or organ of origin: Rectosigmoid junction; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 26; days to sample procurement: 0; initial weight: 530.0; portion submitter id: TCGA-AF-A56N-01A-12; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 5.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 5.0; percent tumor cells: 70.0; percent tumor nuclei: 60.0;